Higuchi et al. reported that combined CTLA-4 antibody and PARP inhibitor therapy in BRCA1-deficient ovarian cancer patients significantly prolonged survival mediated by T cells [17]. This evidence concerns the gene BRCA1 and ovarian carcinoma.